2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 773

The Immunophenotyping of Peripheral Blood Associates with Nailfold Microvascular Changes in Patients with Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 198

The Impact of Electronic Consults (E-Consults) on Positive ANA Referrals in a Veteran Population

Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 230

The Impact of Limited Health Literacy on Patient-Reported Outcomes (PROs) in Systemic Lupus Erythematosus (SLE)

ARHP Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 348

The Impact of Rheumatoid Arthritis-Sustained Remission on Patient´s Reported Outcomes Differs Accordingly to Each Particular Outcome

Patient Outcomes, Preferences, and Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 416

The Impact of Therapy on Anti-Carbamylated Protein Antibody Isotypes and Serostatus in Patients with Early RA Treated with Abatacept and MTX

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 822

The Incidence Rate of Deep Vein Thrombosis and/or Pulmonary Embolism in Patients with Giant Cell Arteritis – Single Center Observational Study

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 497

The JAK1 Selective Inhibitor Filgotinib Regulates Both Enthesis and Colon Inflammation in a Mouse Model of Psoriatic Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

9:00AM-11:00AM: Abstract Number: 482

The Link between ACPA and Erosion Development: Is ACPA Sufficient? an Association Study in Clinically Suspect Arthralgia

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 518

The Occurrence of Shingles and the Effect of Zoster Vaccination with the Use of Methotrexate in Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

9:00AM-11:00AM: Abstract Number: 494

The Oral Microbiome Is Altered in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 67

The Oxygen Sensor PHD1 Is an Indispensable Regulator of Arthritis Development

Biology and Pathology of Bone and Joint Poster I

9:00AM-11:00AM: Abstract Number: 345

The Patient Experience of Musculoskeletal Imaging Tests for Investigation of Inflammatory Arthritis: A Mixed Methods Study

Patient Outcomes, Preferences, and Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 319

The Placebo-Controlled Fracture Study in Postmenopausal Women with Osteoporosis: The Foundation Effect of Rebuilding Bone with One Year of Romosozumab Leads to Continued Lower Fracture Risk after Transition to Denosumab

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 324

The Predictors of the Efficacy of Denosumab, a Monoclonal Antibody to RANK Ligand, on Osteoporosis in Rheumatoid Arthritis Patients from Japanese Multicenter Study

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 683

The Presence of Anti-Ro and Anti-La Antibodies Is Associated with Tubulointerstitial Damage in Lupus Nephritis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].